ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
M. Ravish Kumar1 , Praveen Kumar Doddamani2, Lavanya S. Peter3, Prashant Parandekar1 and Shrinivas Reddy4
1Department of Microbiology, ESIC Medical College and Hospital, K.K Nagar, Chennai, Tamilnadu, India.
2Department of Microbiology, ESIC Medical College and Hospital, Rajajinagar, Bengaluru, Karnataka, India.
3Department of Pulmonary Medicine MBBS, MD, ESIC Medical College and Hospital, Sedam Road, Kalaburagi, Karnataka, India.
4Department of Community Medicine, ESIC Medical College and Hospital, Sedam Road, Kalaburagi, Karnataka, India.
Article Number: 9207 | © The Author(s). 2024
J Pure Appl Microbiol. 2024;18(2):1290-1296.
Received: 26 December 2023 | Accepted: 10 May 2024 | Published online: 02 June 2024
Issue online: June 2024

Tuberculosis (TB) is a serious disease that has been observed since ancient times. In the mid-to late-20th century, the main clinical approach to this disease involved focusing on its diagnosis, prevention, and treatment. However, in the 21st century, the focus has shifted toward the diagnosis and treatment of drug-resistant TB. With the use of the Xpert MTB/RIF assay at the frontlines in India, interpreting indeterminate results to treatment with rifampicin, an antitubercular drug, can be challenging. This is further exacerbated by a lack of knowledge regarding mutation frequency in antitubercular drug-resistant genes in this region. Among antitubercular drugs, rifampicin is the most potent and effective drug for the treatment of tuberculosis; hence, understanding the pattern of rifampicin resistance (rpoB) gene mutations will provide insights into the genetic basis of this resistance, which may help in the prevention and treatment of TB. This retrospective observational study presents sociodemographic details, sample types, Mycobacterium tuberculosis load, types of probe mutations detected, and rifampicin indeterminate results from the Xpert MTB/RIF assay. Of the 314 samples analyzed, 258 showed rifampicin resistance as detected by MTB, with 56 samples of MTB-detected rifampicin indeterminate results. Type E probe mutation (58.9%) was the most common type, while the least frequent mutation was Type C probe (1.5%). No missing probe was observed in approximately 8.9% of samples. Among the 56 rifampicin indeterminate results, the maximum Cycle threshold value did not cross 34.5 in six samples.


Xpert MTB/RIF, rpoB Mutation, Rifampicin Indeterminate

Article Metrics

Article View: 114

Share This Article

© The Author(s) 2024. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.